# A Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease (AD)

> **NCT05256134** · PHASE3 · TERMINATED · sponsor: **Hoffmann-La Roche** · enrollment: 25 (actual)

## Conditions studied

- Alzheimers Disease

## Interventions

- **DRUG:** Gantenerumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05256134
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-04-19
- **Primary completion:** 2023-03-13
- **Final completion:** 2023-03-13
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** Decision to terminate development of gantenerumab for treatment of people at risk for or at earliest stages of Alzheimer disease (AD) following results of a pre-planned analysis of safety \& efficacy of gantenerumab in Graduate I\&II (WN29922/WN39658).
- **Last updated:** 2025-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05256134

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05256134, "A Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease (AD)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05256134. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*